Vyoshadi Guggulu: Benefits, Evidence & Safety

Q: Does Vyoshadi Guggulu help with weight loss?

A 12week CCRAS study of 100 obese adults reported significant BMI, waist, and cholesterol reductions: but it was openlabel, had no placebo group, and combined the tablet with vidanga churna. Small comparative trials agree directionally. Evidence is promising but not conclusive.

Q: What are common side effects?

The bestdocumented effects are skin rash (hypersensitivity, seen in ~9% of guggulipid users in one RCT) and loose stools or mild GI upset, especially at higher doses or on an empty stomach. Lower the dose or stop if a rash appears.

TL;DR

Vyoshadi Guggulu is a classical guggulu (Commiphora mukul) tablet with trikatu, triphala, chitraka, musta, and vidanga, traditionally used for obesity and joint disorders. A 12-week CCRAS multicenter study in 100 obese adults found significant drops in BMI, waist circumference, and cholesterol with no reported adverse reactions (open-label, no placebo). (55 words. Sources: PMC12231980, planetayurveda, AlkaPharmacy)

What it is

Vyoshadi Guggulu (also sold as Navaka Guggul / Vyosadi Vati) is a classical Ayurvedic tablet standardized in the Ayurvedic Formulary of India (AFI Part-I, 5:9; API Part-II, Vol-II) (per the CCRAS trial report). Per the AFI ingredient list, it contains harde (haritaki), baheda, amla (the three of triphala), dried ginger, black pepper, long pepper (the three of trikatu/vyosha), chitrak (Plumbago zeylanica), nagarmotha (Cyperus rotundus), vavding (Embelia ribes), and purified guggulu resin: roughly 50% of the formula by weight (AFI list via AlkaPharmacy). Its classical reference is Ashtanga Hridaya, Chikitsa Sthana 29/49–54, where it is indicated for medoroga (obesity) and vata–kapha disorders (reference and indications per Planet Ayurveda).

Traditional use

Classically it is a lekhana (scraping/reducing) formula used for medoroga (obesity), kapha disorders, amavata (rheumatic/joint conditions), swelling, and sluggish digestion (same). The 2025 IRJAY comparative trial paper lists its roga-karma as medo roga, kapha roga, and amavata (IJAPR/Irjay paper). Traditional indications are classical claims, not proven outcomes.

What modern research says

Prospective open-label multicenter study (human): The CCRAS trial (n=100 obese adults, 2 centers) gave Vyoshadi Guggulu 1 g thrice daily plus vidanga churna 3 g twice daily for 12 weeks. Investigators reported statistically significant reductions in BMI (p=0.016), waist circumference (p=0.043), and serum cholesterol (p=0.002), with improvements in breathlessness, fatigue, and excessive sweating: and no adverse drug reactions reported (PMCID PMC12231980, PMID 40626154). Caveats: open-label, no placebo or control arm, and it was combined with vidanga churna, so the effect cannot be attributed to Vyoshadi Guggulu alone.
Small comparative trial: A 30-patient, 45-day study found ~5.9% weight and ~6.5% BMI reduction with Vyoshadi Guggulu alone, and larger reductions when combined with Bilwadi Kwath: again small, short, and unblinded (IRJAY 2020).
Important negative evidence: A rigorous US randomized, double-blind, placebo-controlled trial (n=103, 8 weeks) of standardized guggulipid, the resin extract at the heart of this formula, found it did NOT lower LDL cholesterol. LDL actually rose 4–5% versus a 5% drop on placebo, and 6 of 67 guggulipid users developed a hypersensitivity rash (JAMA 2003, PMID 12915429). This trial tested the extract, not the full polyherbal tablet, but it is the strongest lipid evidence on guggulu and contradicts the "cholesterol-lowering" marketing claim.

Dosage

This section reports only authoritative regimens: it is not a personal recommendation.

Clinical-trial regimen: The CCRAS study used 2 tablets of 500 mg (1 g total) thrice daily after meals with lukewarm water for 12 weeks, alongside vidanga churna 3 g twice daily (PMC12231980).
Formulary reference: A WJPR review of classical guggulu preparations lists the traditional dose as ~3 g/day with warm water (WJPR).

Use only under a qualified practitioner's supervision.

Safety & contraindications

Guggulu-specific effects: The JAMA RCT reported hypersensitivity skin rash in 6 of 67 users (none on placebo); gastrointestinal looseness/diarrhea is also reported. Impure or residue-laden guggulu can cause headaches and GI upset (JAMA RCT; safety notes). Bleeding: In vitro and preliminary clinical studies suggest guggulu may have antiplatelet effects, so combining it with anticoagulants or antiplatelets could theoretically raise bleeding risk: use caution with warfarin, aspirin, or similar drugs and discuss it with your clinician (interaction evidence review). Thyroid: A pilot clinical trial of Vyoshadi Guggulu itself in subclinical hypothyroidism found serum TSH fell significantly (about 17%), so people with thyroid disease or on thyroid medication should monitor levels and consult a doctor (PMC8966764). Pregnancy/breastfeeding/children: Safety data is limited: avoid without clinician guidance. Ulcers/gastritis: The warming spices (trikatu, chitrak) may irritate the stomach lining. Avoid in active peptic ulcer or gastritis. Bottom line on lipids: Do not use it as a substitute for prescribed cholesterol medication: the best RCT evidence found no LDL benefit.

FAQs

Does Vyoshadi Guggulu help with weight loss?

A 12-week CCRAS study of 100 obese adults reported significant BMI, waist, and cholesterol reductions: but it was open-label, had no placebo group, and combined the tablet with vidanga churna. Small comparative trials agree directionally. Evidence is promising but not conclusive.

Does it lower cholesterol?

The full tablet was associated with lower serum cholesterol in one open-label study, but the strongest evidence on its key ingredient says otherwise: a US RCT found standardized guggulipid did not lower LDL and slightly raised it. Do not rely on it for cholesterol control.

What is the classical dose?

Traditional and formulary sources suggest around 1–3 g/day in divided doses with warm water; the CCRAS trial used 1 g thrice daily after meals. Dosing should be individualized by a qualified Ayurvedic practitioner, not self-prescribed from this page.

Can I take it with blood thinners?

Be cautious. Guggulu may have mild antiplatelet activity, and combining it with anticoagulants or antiplatelets could raise bleeding risk. Tell your doctor about all Ayurvedic medicines if you take warfarin, aspirin, or similar drugs.

Is it safe in pregnancy?

Safety data in pregnancy and breastfeeding is limited, so it is generally avoided. Classical texts sometimes use guggulu formulations broadly, but that is not safety evidence: consult a clinician.

What are common side effects?

The best-documented effects are skin rash (hypersensitivity, seen in ~9% of guggulipid users in one RCT) and loose stools or mild GI upset, especially at higher doses or on an empty stomach. Lower the dose or stop if a rash appears.

Can it replace my statin?

No. There is no evidence it matches statins for lipid lowering, and the only rigorous RCT of its core ingredient found no LDL benefit. Stopping prescribed cholesterol medication for an herbal tablet risks heart attack and stroke: discuss any change with your cardiologist.

Sources

Tier 1 (API/AFI/CCRAS/WHO/peer-reviewed):

"Clinical Safety and Efficacy of Ayurveda Multi-Herbal Formulation in the Management of Obesity," CCRAS multicenter open-label study (PMID 40626154, PMCID PMC12231980) — PMC · PMC12231980
Szapary et al., "Guggulipid for the Treatment of Hypercholesterolemia: A Randomized Controlled Trial," JAMA 2003 (PMID 12915429) — PubMed · PMID 12915429
AFI Part-I (5:9) / API Part-II Vol-II standardization status (as stated in the CCRAS trial)
"Efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of subclinical hypothyroidism," open-label randomized comparative pilot trial (PMCID PMC8966764) — PMC · PMC8966764

Tier 2 (PubMed-indexed/other journals):

Comparative clinical study of Vyoshadi Guggulu and Bilwadi Kwath in Sthaulya, IRJAY 2020 — irjay.com
Vyoshadi Guggulu vs Triphala Churna comparative study, Int J Ayur Pharma Res 2025 — ijapr.in
Guggulu preparations review incl. Vyoshadi Guggulu dose, WJPR — wjpr.s3.ap-south-1.amazonaws.com

Tier 3 (classical aggregators / vendor pages, labeled as such):

Vyoshadi Guggulu classical reference (Ashtanga Hridaya Chikitsa 29/49–54), ingredients, uses (aggregator) — planetayurveda.com
AFI ingredient list (vendor) — alkapharmacy.com
Side-effect and precaution notes (aggregator) — ask-ayurveda.com

[Triphala Churna](/learn/herbs/triphala-churna)
[Ashwagandha](/learn/herbs/ashwagandha)
[Tulsi](/learn/herbs/tulsi)

This article is for educational purposes only and is not medical advice. Consult a qualified practitioner before using any Ayurvedic formulation.